The Big Picture: Why We Do What We Do - Taking the Sting out of Hepatitis C

In the beginning, there was sofosbuvir (SovaldiTM), the first drug approved by the FDA to be used without interferon for some types of hepatitis C (HCV). Sofosbuvir comes in a once-a-day pill. It takes 12 weeks to work, and it cures up to 90% of people with genotype 2 and genotype 3 hepatitis C. Then came sofosbuvir in combination with ledipasvir (HarvoniTM), which within that same, 12-week time frame has been proven to cure hepatitis C in a majority of people with genotype 1.

Sofosbuvir and ledipasvir both work by attaching to crucial parts of the HCV replication machinery to stop the virus from copying itself. To learn more about the HCV combo breakthrough therapy consisting of the HCV NS5B inhibitor, sofosbuvir, and the HCV NS5A inhibitor, ledipasvir, watch this presentation.

But theory and medical practice are two different things. What do patients think? Please read this interesting blog by hepatitis C advocate and health educator Lucinda Porter, who was cured of HCV by HarvoniTM during a clinical trial.

QPS is thankful that Gilead let us play a small yet significant role in developing SovaldiTM and HarvoniTM. Hopefully, our continued involvement with HCV research will lead to better treatment options for other genotypes, and reach the millions of people yet to be diagnosed. QPS is proud of the work we do in helping to provide patients with safe, effective and reliable medicines - bottom line, it’s what we’re here for.

20 years in pharma R&D navigation